New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
08:07 EDTMSTXMast Therapeutics reports positive data from MST-188 study
Mast Therapeutics announced new data from its randomized, placebo-controlled, nonclinical study of MST-188 in a model of chronic heart failure. MST-188 resulted in statistically significant and progressive reductions in troponin-I, at both 1 week and 2 weeks after MST-188 administration. Specifically, at 2 weeks post-administration, compared to baseline values, mean reduction troponin was 46.7% for low-dose MST-188 and 48.8% for high-dose MST-188. In contrast, troponin increased 7.7% in the control group.
News For MSTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 25, 2015
12:40 EDTMSTXMast Therapeutics COO Patrick Keran to step down
Mast Therapeutics announced a management change in connection with a restructuring of management to best support the company in its current stage of development. The company's President and COO, Patrick L. Keran, will step down from that role and be leaving the company effective February 28, 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use